ロキサダスタットの世界市場レポート 2025年

ロキサダスタット市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で91億6,000万米ドルに成長します。予測期間における成長の背景には、新たな適応症のための継続的な調査、ヘルスケア支出の増加、非注射貧血治療に対する需要の高まり、償還政策の拡大、高齢者人口の増加があります。主な動向としては、経口貧血治療薬へのシフト、代替療法との競合激化、ライセンス契約の拡大、低酸素誘導因子研究への投資拡大、患者中心の治療アプローチへの重点化などが挙げられます。

慢性腎臓病（CKD）の有病率の上昇は、ロキサダスタット市場の成長を牽引すると予想されます。CKDは、腎機能が時間とともに悪化する進行性の病態であり、適切に管理されなければしばしば腎不全に至る。CKDの罹患率が増加している主な原因は、人口の高齢化、糖尿病や高血圧の罹患率の増加、不健康なライフスタイルの選択などです。ロキサダスタットは、エリスロポエチンの産生を刺激することによってCKDに関連する貧血を管理する重要な治療法であり、赤血球レベルを高め、腎機能全体と患者のQOLを向上させる。例えば、2024年12月、オーストラリアの政府機関であるオーストラリア保健福祉研究所（AIHW）は、CKD死亡率が毎年上昇し、2021年には4.2％、2022年には6.2％増加すると報告しました。その結果、CKD症例の増加がロキサダスタットの需要を促進しています。

アイルランドのHigh-Tech Drugs Schemeのような償還制度の拡大は、患者にとってロキサダスタットをより利用しやすくすることで、ロキサダスタットの市場成長を加速させています。アイルランドの政府管理プログラムであるHigh-Tech Drugs Schemeは、高額で特殊な医薬品を対象としており、患者の経済的障壁を軽減し、より広範な採用を支援しています。例えば、2022年9月、米国の製薬会社アステラス製薬は、EVRENZO（ロキサダスタット）がアイルランドのハイテク医薬品制度で償還を受けたと発表しました。ロキサダスタットは、アイルランドで承認された初の経口投与低酸素誘導因子プロリルヒドロキシラーゼ（HIF-PH）阻害剤で、透析の状況や赤血球造血刺激因子（ESA）治療の既往にかかわらず、CKD患者の目標ヘモグロビン値（10～12g/dL）の達成・維持に有効であることが実証されました。このような保険償還の取り組みは、患者のアクセスを向上させ、市場拡大の原動力になると期待されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ロキサダスタット PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のロキサダスタット市場：成長率分析
• 世界のロキサダスタット市場の実績：規模と成長, 2019-2024
• 世界のロキサダスタット市場の予測：規模と成長, 2024-2029, 2034F
• 世界ロキサダスタット総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のロキサダスタット市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 20mg
• 50mg
• 世界のロキサダスタット市場製品の配合、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠
• 世界のロキサダスタット市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門薬局
• 透析センター
• 世界のロキサダスタット市場エンドユーザーアプリケーション別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性腎臓病関連貧血
• その他の貧血症状

第7章 地域別・国別分析

• 世界のロキサダスタット市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のロキサダスタット市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ロキサダスタット市場：競合情勢
• ロキサダスタット市場：企業プロファイル
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Hetero Drugs Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Akebia Therapeutics Inc.
• Metrochem API Private Limited
• FibroGen Inc.
• AMI Lifesciences
• Lee Pharma Ltd.
• Faran Shimi Pharmaceutical Company
• Maithri Drugs Pvt. Ltd.
• Clearsynth Labs Ltd.
• Bal Pharma
• HEMA Pharmaceuticals Pvt. Ltd.
• Zhejiang Hengkang Pharmaceutical Co. Ltd.
• Kimia Biosciences Pvt. Ltd.
• Lewens Labs Pvt. Ltd.
• Hangzhou Longshine Bio-Tech Co. Ltd.
• GLR Innovations

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ロキサダスタット市場2029：新たな機会を提供する国
• ロキサダスタット市場2029：新たな機会を提供するセグメント
• ロキサダスタット市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, promoting increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without requiring exogenous erythropoiesis-stimulating agents. It is primarily used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production.

The main types of Roxadustat include 20 mg and 50 mg formulations. The 20 mg variant is an oral HIF-PHI used for treating anemia associated with chronic kidney disease by stimulating endogenous erythropoietin production. Roxadustat is available in oral tablet form and is distributed through hospitals, specialty pharmacies, and dialysis centers. It is primarily used for chronic kidney disease-associated anemia and other related conditions.

The Roxadustat market research report is one of a series of new reports from The Business Research Company that provides Roxadustat market statistics, including Roxadustat industry global market size, regional shares, competitors with a Roxadustat market share, detailed Roxadustat market segments, market trends and opportunities, and any further data you may need to thrive in the Roxadustat industry. This Roxadustat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Roxadustat market size has grown strongly in recent years. It will grow from $6.44 billion in 2024 to $6.92 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to regulatory approvals in major markets, strong clinical trial results, the increasing prevalence of chronic kidney disease, rising awareness of anemia management, and government support for anemia treatments.

The Roxadustat market size is expected to see strong growth in the next few years. It will grow to $9.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to ongoing research for new indications, increasing healthcare expenditure, rising demand for non-injectable anemia treatments, expanding reimbursement policies, and a growing geriatric population. Major trends include a shift toward oral anemia treatments, increasing competition from alternative therapies, the expansion of licensing agreements, growing investment in hypoxia-inducible factor research, and a stronger focus on patient-centric treatment approaches.

The rising prevalence of chronic kidney disease (CKD) is expected to drive the growth of the Roxadustat market. CKD is a progressive condition where kidney function deteriorates over time, often leading to kidney failure if not properly managed. The increasing incidence of CKD is primarily due to aging populations, higher rates of diabetes and hypertension, and unhealthy lifestyle choices. Roxadustat is a key treatment for managing CKD-related anemia by stimulating erythropoietin production, which boosts red blood cell levels and enhances overall kidney function and patient quality of life. For instance, in December 2024, the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, reported an annual rise in CKD mortality rates, with increases of 4.2% in 2021 and 6.2% in 2022. As a result, the growing number of CKD cases is fueling the demand for Roxadustat.

The expansion of reimbursement programs, such as Ireland's High-Tech Drugs Scheme, is accelerating Roxadustat's market growth by making it more accessible to patients. The High-Tech Drugs Scheme, a government-managed program in Ireland, covers high-cost, specialized medications, reducing financial barriers for patients and supporting broader adoption. For example, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company, announced that EVRENZO (Roxadustat) received reimbursement under Ireland's High-Tech Drugs Scheme. Roxadustat, the first orally administered hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in Ireland, demonstrated effectiveness in achieving and maintaining target hemoglobin levels (10-12g/dL) in CKD patients, regardless of their dialysis status or previous erythropoiesis-stimulating agent (ESA) treatment. Such reimbursement initiatives are expected to enhance patient access and drive market expansion.

In February 2024, FibroGen Inc., a US-based biopharmaceutical company, partnered with Astellas Pharma Inc. and AstraZeneca PLC to further develop and distribute Roxadustat for anemia associated with CKD and other conditions, such as myelodysplastic syndromes (MDS). Astellas Pharma, a Japan-based pharmaceutical company, and AstraZeneca, a UK-based pharmaceutical giant, bring extensive expertise in global commercialization, further boosting Roxadustat's market potential. These partnerships highlight the growing investment and focus on expanding treatment options for CKD-related anemia, solidifying Roxadustat's position in the market.

Major players in the Roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Roxadustat report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Roxadustat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Roxadustat market consists of sales of products such as 70 mg, 100 mg, and 150 mg film-coated tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Roxadustat Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on roxadustat market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for roxadustat ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The roxadustat market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 20mg; 50mg
• 2) By Product Formulation: Oral Tablets
• 3) By Distribution Channel: Hospitals; Specialty Pharmacies; Dialysis Centers
• 4) By End-User Application: Chronic Kidney Disease-Associated Anemia; Other Anemia Conditions
• Companies Mentioned: AstraZeneca PLC; Viatris Inc.; Astellas Pharma Inc.; Dr. Reddy's Laboratories Ltd.; Hetero Drugs Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Roxadustat Market Characteristics

3. Roxadustat Market Trends And Strategies

4. Roxadustat Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Roxadustat Growth Analysis And Strategic Analysis Framework

• 5.1. Global Roxadustat PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Roxadustat Market Growth Rate Analysis
• 5.4. Global Roxadustat Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Roxadustat Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Roxadustat Total Addressable Market (TAM)

6. Roxadustat Market Segmentation

• 6.1. Global Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20mg
• 50mg
• 6.2. Global Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• 6.3. Global Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Pharmacies
• Dialysis Centers
• 6.4. Global Roxadustat Market, Segmentation By End-User Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Kidney Disease-Associated Anemia
• Other Anemia Conditions

7. Roxadustat Market Regional And Country Analysis

• 7.1. Global Roxadustat Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Roxadustat Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Roxadustat Market

• 8.1. Asia-Pacific Roxadustat Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Roxadustat Market

• 9.1. China Roxadustat Market Overview
• 9.2. China Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Roxadustat Market

• 10.1. India Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Roxadustat Market

• 11.1. Japan Roxadustat Market Overview
• 11.2. Japan Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Roxadustat Market

• 12.1. Australia Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Roxadustat Market

• 13.1. Indonesia Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Roxadustat Market

• 14.1. South Korea Roxadustat Market Overview
• 14.2. South Korea Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Roxadustat Market

• 15.1. Western Europe Roxadustat Market Overview
• 15.2. Western Europe Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Roxadustat Market

• 16.1. UK Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Roxadustat Market

• 17.1. Germany Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Roxadustat Market

• 18.1. France Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Roxadustat Market

• 19.1. Italy Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Roxadustat Market

• 20.1. Spain Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Roxadustat Market

• 21.1. Eastern Europe Roxadustat Market Overview
• 21.2. Eastern Europe Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Roxadustat Market

• 22.1. Russia Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Roxadustat Market

• 23.1. North America Roxadustat Market Overview
• 23.2. North America Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Roxadustat Market

• 24.1. USA Roxadustat Market Overview
• 24.2. USA Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Roxadustat Market

• 25.1. Canada Roxadustat Market Overview
• 25.2. Canada Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Roxadustat Market

• 26.1. South America Roxadustat Market Overview
• 26.2. South America Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Roxadustat Market

• 27.1. Brazil Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Roxadustat Market

• 28.1. Middle East Roxadustat Market Overview
• 28.2. Middle East Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Roxadustat Market

• 29.1. Africa Roxadustat Market Overview
• 29.2. Africa Roxadustat Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Roxadustat Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Roxadustat Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Roxadustat Market Competitive Landscape And Company Profiles

• 30.1. Roxadustat Market Competitive Landscape
• 30.2. Roxadustat Market Company Profiles
  • 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hetero Drugs Limited Overview, Products and Services, Strategy and Financial Analysis

31. Roxadustat Market Other Major And Innovative Companies

• 31.1. Akebia Therapeutics Inc.
• 31.2. Metrochem API Private Limited
• 31.3. FibroGen Inc.
• 31.4. AMI Lifesciences
• 31.5. Lee Pharma Ltd.
• 31.6. Faran Shimi Pharmaceutical Company
• 31.7. Maithri Drugs Pvt. Ltd.
• 31.8. Clearsynth Labs Ltd.
• 31.9. Bal Pharma
• 31.10. HEMA Pharmaceuticals Pvt. Ltd.
• 31.11. Zhejiang Hengkang Pharmaceutical Co. Ltd.
• 31.12. Kimia Biosciences Pvt. Ltd.
• 31.13. Lewens Labs Pvt. Ltd.
• 31.14. Hangzhou Longshine Bio-Tech Co. Ltd.
• 31.15. GLR Innovations

32. Global Roxadustat Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Roxadustat Market

34. Recent Developments In The Roxadustat Market

35. Roxadustat Market High Potential Countries, Segments and Strategies

• 35.1 Roxadustat Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Roxadustat Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Roxadustat Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer